title: Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing.
abstract: Infantile spasms (IS) are a unique and severe form of epilepsy associated with poor neurologic and developmental outcomes. The refractory spasms and abnormal electroencephalogram (EEG) patterns associated with the condition are believed to have a progressively detrimental impact. Therefore, rapid and complete control of spasms is the primary goal of treatment. Well-controlled clinical trials in Europe, Canada, and the United States have demonstrated that vigabatrin is efficacious and generally well-tolerated as monotherapy for IS. Several key studies, including pivotal trials that led to United States approval of vigabatrin in 2009, as well as comparative trials of vigabatrin and hormonal treatment, are the focus of this review. All studies assessed spasm cessation - usually as the primary endpoint - and adverse events. Vigabatrin dosages generally ranging from 100 to 150 mg/kg/day demonstrated efficacy to decrease or eradicate spasms and eliminate hypsarrhythmic EEG in patients with newly diagnosed IS. Several studies demonstrated long-term sustainability of spasm freedom with no negative impact on developmental outcomes. Vigabatrin was generally well-tolerated with few severe adverse events. Visual field defects cannot be adequately assessed in infants and young children, so this potential adverse effect was not evaluated in children with spasms. Notably, the time to response with vigabatrin was very rapid, generally occurring within 2 weeks of initial treatment. This allows for early treatment modification as needed. For infants who respond well to vigabatrin, treatment duration up to 6 months appears to be appropriate for realizing spasm freedom while limiting potential risks of adverse events and recurrences.
authors: Division of Neurology, Université de Montréal, Montreal, QC, Canada. lionel.carmant@umontreal.ca
authors: L
authors: L
authors: Carmant
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced; D005060:Europe; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007508:Irritable Mood / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013036:Spasms, Infantile / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D020888:Vigabatrin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin